Platelet-activating factor (PAF) and PAF antagonists in asthma. 1990

D Hosford, and J M Mencia-Huerta, and P Braquet
Institut Henri Beaufour, Le Plessis, France.

PAF is produced by and activates inflammatory cells, such as monocytes/macrophages, mast cells, platelets, neutrophils, eosinophils and endothelial cells. Its ability to imitate anaphylaxis, inducing for instance bronchoconstriction (BC) in guinea-pigs, and its identification (and/or that of lyso-PAF) in exudates from shocked lungs, led to the hypothesis that PAF is involved in immediate hypersensitivity. Recent results of Bachelet et al. show that PAF reduces the increased cyclic AMP content of guinea-pig alveolar cell population exposed to PGE2, salbutamol or isoprenaline, which agrees with its hypothesized stimulating role in conditions where increased cyclic AMP may reduce mediator release. PAF antagonists are usually selected with in vitro platelet tests and their in vivo activity is characterized in normal animals. Recent data of Pretolani et al. demonstrate nevertheless that the antagonists may lose part of their ability to inhibit PAF itself if tested on lungs from actively sensitized guinea-pigs. These lungs differ from those of passively sensitized or of naive animals in that they become hyper-responsive to mediators (PAF, leukotriene D4 [LTD4], histamine, arachidonate [AA]): BC and formation of thromboxane A2 are enhanced, and histamine is released dose-dependently under conditions where it is absent from perfusates from LTD4, AA or PAF-stimulated naive lungs. Peripheral inflammatory cells (basophils, eosinophils, monocytes) are possibly recruited into the lungs of the actively sensitized animals sometime during the second and/or third week of sensitization, and provide a new target which may account for the enhanced lung responsiveness. Ultra-structural studies of Lellouch-Tubiana et al. (abstract in this meeting) support this concept. Neither the primary target nor the chemotactic substance responsible for the reported modifications are identified, but recent data of Bachelet et al, showing that alveolar populations from actively sensitized guinea-pigs are less responsive to the cyclic AMP stimulating effects of PGE2, salbutamol or isoprenaline suggest the existence of a cell defect which may be important for the triggering of allergen-induced BC and cell recruitment. Our present concept involves a "pre-inflamed" lung in actively sensitized guinea-pigs and in human asthmatics, a stand-by process following sensitization and which is revealed following the activation of a target cell. This may be the alveolar macrophage which releases substances (PAF, TXA2, IL1) likely to start BC and protracted cell recruitment and activation.

UI MeSH Term Description Entries
D006967 Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen. Allergy,Allergic Reaction,Allergic Reactions,Allergies,Hypersensitivities,Reaction, Allergic,Reactions, Allergic
D010972 Platelet Activating Factor A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. AGEPC,Acetyl Glyceryl Ether Phosphorylcholine,PAF-Acether,Phosphorylcholine, Acetyl Glyceryl Ether,1-Alkyl-2-acetyl-sn-glycerophosphocholine,Platelet Aggregating Factor,Platelet Aggregation Enhancing Factor,Platelet-Activating Substance,Thrombocyte Aggregating Activity,1 Alkyl 2 acetyl sn glycerophosphocholine,Aggregating Factor, Platelet,Factor, Platelet Activating,PAF Acether,Platelet Activating Substance
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas

Related Publications

D Hosford, and J M Mencia-Huerta, and P Braquet
February 1991, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
D Hosford, and J M Mencia-Huerta, and P Braquet
January 2013, Fitoterapia,
D Hosford, and J M Mencia-Huerta, and P Braquet
April 1992, Sheng li ke xue jin zhan [Progress in physiology],
D Hosford, and J M Mencia-Huerta, and P Braquet
January 1989, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi,
D Hosford, and J M Mencia-Huerta, and P Braquet
January 1987, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
D Hosford, and J M Mencia-Huerta, and P Braquet
June 1989, Medizinische Monatsschrift fur Pharmazeuten,
D Hosford, and J M Mencia-Huerta, and P Braquet
January 1990, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi,
D Hosford, and J M Mencia-Huerta, and P Braquet
December 2007, Bioorganic & medicinal chemistry letters,
D Hosford, and J M Mencia-Huerta, and P Braquet
January 2008, Recent patents on inflammation & allergy drug discovery,
D Hosford, and J M Mencia-Huerta, and P Braquet
July 2000, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Copied contents to your clipboard!